TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities April 17, 2024
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 6, 2024
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 February 26, 2024
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition December 11, 2023
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer December 5, 2023